Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia

Daniel Truong, Matthew Brodsky, Mark Lew, Allison Brashear, Joseph Jankovic, Eric Molho, Olga Orlova, Sofia Timerbaeva

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport®, Ipsen Biopharm Ltd.) for the treatment of cervical dystonia (CD) and the long-term safety and efficacy of repeated treatments. During the randomized, double-blind, placebo-controlled phase patients were randomized to 500 units Dysport (n = 55) or placebo (n = 61). Efficacy assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total and subscale scores, visual analogue scale (VAS) for pain, subject/investigator's VAS for symptom assessments. Patients completing the double-blind treatment could enter an open-label extension phase and receive up to 4 additional Dysport treatments. Dysport produced a significant decrease from baseline in mean (±SE) TWSTRS total scores compared with placebo at Week 4 (primary efficacy endpoint; -15.6 ± 2.0 vs. -6.7 ± 2.0; p < 0.001) with significant improvements sustained to Week 12 (p = 0.019). Dysport also produced significant improvements in TWSTRS subscale scores, VAS pain scores, and subject/investigator's VAS symptom assessments compared to placebo. The mean duration of open-label study participation was 51.9 weeks (range 3.9-94.0 weeks). During open-label treatment, all treatment cycles resulted in improvements in mean TWSTRS total and subscale scores at Week 4 post-treatment; greatest improvement was seen in cycle 1. The mean duration between treatment cycles was 15-17 weeks. Dysport demonstrated a good long-term safety profile; most adverse events were mild or moderate and typical of the known safety profile of Dysport in this indication. These results confirm that Dysport (500 units) is safe, effective, and well-tolerated in patients with CD.

Original languageEnglish (US)
Pages (from-to)316-323
Number of pages8
JournalParkinsonism and Related Disorders
Volume16
Issue number5
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Torticollis
Type A Botulinum Toxins
Safety
Placebos
Symptom Assessment
Pain Measurement
Visual Analog Scale
Therapeutics
Research Personnel
abobotulinumtoxinA

Keywords

  • Botulinum toxin type A
  • Cervical dystonia
  • Dysport
  • Randomized, controlled trial
  • Spasmodic torticollis

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. / Truong, Daniel; Brodsky, Matthew; Lew, Mark; Brashear, Allison; Jankovic, Joseph; Molho, Eric; Orlova, Olga; Timerbaeva, Sofia.

In: Parkinsonism and Related Disorders, Vol. 16, No. 5, 01.06.2010, p. 316-323.

Research output: Contribution to journalArticle

Truong, D, Brodsky, M, Lew, M, Brashear, A, Jankovic, J, Molho, E, Orlova, O & Timerbaeva, S 2010, 'Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia', Parkinsonism and Related Disorders, vol. 16, no. 5, pp. 316-323. https://doi.org/10.1016/j.parkreldis.2010.03.002
Truong, Daniel ; Brodsky, Matthew ; Lew, Mark ; Brashear, Allison ; Jankovic, Joseph ; Molho, Eric ; Orlova, Olga ; Timerbaeva, Sofia. / Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. In: Parkinsonism and Related Disorders. 2010 ; Vol. 16, No. 5. pp. 316-323.
@article{75b2c2a886274dfa9dcca0490606b0b9,
title = "Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia",
abstract = "The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport{\circledR}, Ipsen Biopharm Ltd.) for the treatment of cervical dystonia (CD) and the long-term safety and efficacy of repeated treatments. During the randomized, double-blind, placebo-controlled phase patients were randomized to 500 units Dysport (n = 55) or placebo (n = 61). Efficacy assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total and subscale scores, visual analogue scale (VAS) for pain, subject/investigator's VAS for symptom assessments. Patients completing the double-blind treatment could enter an open-label extension phase and receive up to 4 additional Dysport treatments. Dysport produced a significant decrease from baseline in mean (±SE) TWSTRS total scores compared with placebo at Week 4 (primary efficacy endpoint; -15.6 ± 2.0 vs. -6.7 ± 2.0; p < 0.001) with significant improvements sustained to Week 12 (p = 0.019). Dysport also produced significant improvements in TWSTRS subscale scores, VAS pain scores, and subject/investigator's VAS symptom assessments compared to placebo. The mean duration of open-label study participation was 51.9 weeks (range 3.9-94.0 weeks). During open-label treatment, all treatment cycles resulted in improvements in mean TWSTRS total and subscale scores at Week 4 post-treatment; greatest improvement was seen in cycle 1. The mean duration between treatment cycles was 15-17 weeks. Dysport demonstrated a good long-term safety profile; most adverse events were mild or moderate and typical of the known safety profile of Dysport in this indication. These results confirm that Dysport (500 units) is safe, effective, and well-tolerated in patients with CD.",
keywords = "Botulinum toxin type A, Cervical dystonia, Dysport, Randomized, controlled trial, Spasmodic torticollis",
author = "Daniel Truong and Matthew Brodsky and Mark Lew and Allison Brashear and Joseph Jankovic and Eric Molho and Olga Orlova and Sofia Timerbaeva",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.parkreldis.2010.03.002",
language = "English (US)",
volume = "16",
pages = "316--323",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia

AU - Truong, Daniel

AU - Brodsky, Matthew

AU - Lew, Mark

AU - Brashear, Allison

AU - Jankovic, Joseph

AU - Molho, Eric

AU - Orlova, Olga

AU - Timerbaeva, Sofia

PY - 2010/6/1

Y1 - 2010/6/1

N2 - The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport®, Ipsen Biopharm Ltd.) for the treatment of cervical dystonia (CD) and the long-term safety and efficacy of repeated treatments. During the randomized, double-blind, placebo-controlled phase patients were randomized to 500 units Dysport (n = 55) or placebo (n = 61). Efficacy assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total and subscale scores, visual analogue scale (VAS) for pain, subject/investigator's VAS for symptom assessments. Patients completing the double-blind treatment could enter an open-label extension phase and receive up to 4 additional Dysport treatments. Dysport produced a significant decrease from baseline in mean (±SE) TWSTRS total scores compared with placebo at Week 4 (primary efficacy endpoint; -15.6 ± 2.0 vs. -6.7 ± 2.0; p < 0.001) with significant improvements sustained to Week 12 (p = 0.019). Dysport also produced significant improvements in TWSTRS subscale scores, VAS pain scores, and subject/investigator's VAS symptom assessments compared to placebo. The mean duration of open-label study participation was 51.9 weeks (range 3.9-94.0 weeks). During open-label treatment, all treatment cycles resulted in improvements in mean TWSTRS total and subscale scores at Week 4 post-treatment; greatest improvement was seen in cycle 1. The mean duration between treatment cycles was 15-17 weeks. Dysport demonstrated a good long-term safety profile; most adverse events were mild or moderate and typical of the known safety profile of Dysport in this indication. These results confirm that Dysport (500 units) is safe, effective, and well-tolerated in patients with CD.

AB - The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport®, Ipsen Biopharm Ltd.) for the treatment of cervical dystonia (CD) and the long-term safety and efficacy of repeated treatments. During the randomized, double-blind, placebo-controlled phase patients were randomized to 500 units Dysport (n = 55) or placebo (n = 61). Efficacy assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total and subscale scores, visual analogue scale (VAS) for pain, subject/investigator's VAS for symptom assessments. Patients completing the double-blind treatment could enter an open-label extension phase and receive up to 4 additional Dysport treatments. Dysport produced a significant decrease from baseline in mean (±SE) TWSTRS total scores compared with placebo at Week 4 (primary efficacy endpoint; -15.6 ± 2.0 vs. -6.7 ± 2.0; p < 0.001) with significant improvements sustained to Week 12 (p = 0.019). Dysport also produced significant improvements in TWSTRS subscale scores, VAS pain scores, and subject/investigator's VAS symptom assessments compared to placebo. The mean duration of open-label study participation was 51.9 weeks (range 3.9-94.0 weeks). During open-label treatment, all treatment cycles resulted in improvements in mean TWSTRS total and subscale scores at Week 4 post-treatment; greatest improvement was seen in cycle 1. The mean duration between treatment cycles was 15-17 weeks. Dysport demonstrated a good long-term safety profile; most adverse events were mild or moderate and typical of the known safety profile of Dysport in this indication. These results confirm that Dysport (500 units) is safe, effective, and well-tolerated in patients with CD.

KW - Botulinum toxin type A

KW - Cervical dystonia

KW - Dysport

KW - Randomized, controlled trial

KW - Spasmodic torticollis

UR - http://www.scopus.com/inward/record.url?scp=77952958535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952958535&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2010.03.002

DO - 10.1016/j.parkreldis.2010.03.002

M3 - Article

C2 - 20359934

AN - SCOPUS:77952958535

VL - 16

SP - 316

EP - 323

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 5

ER -